Core Viewpoint - The company has received official approval from the National Medical Products Administration of China for its G-BranchTM thoracoabdominal aortic stent graft system, which is designed for the treatment of thoracoabdominal aortic aneurysms (TAAA) [1][2] Group 1 - The G-BranchTM system is a pioneering product featuring a "dual inner and dual outer" hybrid branch design, allowing for full endovascular reconstruction of TAAA while maintaining blood supply to vital organs during the procedure [1] - The company holds independent intellectual property rights for the G-BranchTM product, which is expected to provide a systematic solution for TAAA patients [1] - The approval of the G-BranchTM system follows the earlier approvals of the aortic arch stent system and aortic covered stent system, enhancing the company's product portfolio in the peripheral vascular intervention field [2] Group 2 - The company aims to offer more flexible, comprehensive, safe, effective, and easy-to-operate solutions for thoracoabdominal aortic aneurysm endovascular reconstruction as commercialization progresses [2] - The company is committed to collaborating with industry experts to advance the development and launch of more urgently needed medical device products, driving growth in the medical device sector [2]
先健科技：G-BranchTM胸腹主动脉覆膜支架系统获得国家药品监督管理局的正式注册批准